To investigate the long-term outcomes of radioiodine therapy (RIT) for juvenile Graves’ disease (GD) and the ultrasonographic changes of the thyroid gland. All of 117 juvenile patients (25 males and 92 females aged 10 to 18 [median 16] years) who had undergone RIT for GD at our clinic between 1999 and 2018 were retrospectively reviewed. Each RIT session was delivered on an outpatient basis. The maximum I dose per treatment was 13.0 mCi, and the total I dose per patient was 3.6-29.9 mCi (median 13.0 mCi). I administration was performed once in 89 patients, twice in 26, and thrice in 2. Ultrasonography of the thyroid gland was regularly performed after RIT. The duration of follow-up after the initial RIT ranged from 4 to 226 (median 95) months. At the latest follow-up more than 12 months after RIT (n=111), the patients’ thyroid functions were overt hypothyroidism (91%), subclinical hypothyroidism (2%), normal (5%), or subclinical hyperthyroidism (2%). New thyroid nodules were detected in 9 patients, 4-17 years after initial RIT. Patients with newly detected thyroid nodules underwent RIT with lower doses of I, and had larger residual thyroid volumes than those without nodules. None of the patients were diagnosed with thyroid cancer or other malignancies during the follow-up period. Over a median follow-up period of 95 months (range 4-226 months) RIT was found to be effective and safe in juvenile GD. However, cumulative evidence from further studies are required to confirm the long-term safety of RIT for juvenile GD.
Early detection of microvascular impairments with optical coherence tomography angiography in diabetic patients without clinical retinopathy: a meta-analysis.
September 28, 2020
The Nucleosome Remodeling and Deacetylation Complex Modulates Chromatin Structure at Sites of Active Transcription to Fine-Tune Gene Expression.
August 15, 2018
Low body mass index is associated with ectopic pregnancy following assisted reproductive techniques: a retrospective study.
June 25, 2020
September 10, 2019
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ENDO: 2020ENDO 2020 Annual Conference has been canceled due to COVID-19. Here are highlights of emerging data that has still been released. Keep an eye out for ENDO Online 2020, which will take place from June 8 to 22.